Revolade eltrombopag regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Revolade eltrombopag in its approved indications - to treat chronic idiopathic thrombocytopenic purpura (ITP) in splenectomized patients who are refractory to other treatments and as a second-line treatment of non-splenectomized patients for whom surgery is contraindicated. The decision is in line with a June preliminary appraisal (see BioCentury, June 14). ...